MabVax Therapeutics
Biopharmaceutical company focused on the commercialization of proprietary anti-cancer immunotherapies.
Launch date
Employees
San Diego California (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$8.0m | Series A | ||
N/A | $1.1m | Grant | |
N/A | $1.8m | Debt | |
N/A | Debt | ||
$5.3m | Series B | ||
N/A | $1.8m | Grant | |
N/A | $12.1m | Debt | |
N/A | N/A | IPO | |
N/A | $11.6m | Post IPO Equity | |
N/A | $4.1m | Post IPO Equity | |
* | N/A | $2.1m | Post IPO Equity |
$11.0m | Post IPO Equity | ||
* | N/A | Post IPO Equity | |
Total Funding | €14.7m |
Recent News about MabVax Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.